PARTNER 3 Trial Shows Equipoise Between SAVR-TAVR at 7 Years in Low-Risk Patients

Background: Transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) demonstrated similar composite outcomes at 5 years in low-risk patients with severe, symptomatic aortic valve stenosis. There is concern regarding the long-term durability of bioprosthetic aortic valves. The PARTNER (the Placement of Aortic Transcatheter Valves) 3 trial demonstrated a similar composite end point (death, stroke, or rehospitalization) between TAVR and SAVR at 5 years. Objective: To report the clinical outcomes at 7 years. Design: Prospective, open-label randomized trial conducted at 71 sites. Participants: Eligible patients had severe, symptomatic aortic valve stenosis with low surgical risk, defined as a Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) score of Methods: Patients were randomized 1:1 to TAVR with a SAPIEN 3 valve, or to SAVR with a bioprosthesis according to the surgeon's discretion. Clinically meaningful revascularization was per more...